Nothing Special   »   [go: up one dir, main page]

WO2016083623A1 - Moyens pour le traitement de la prééclampsie - Google Patents

Moyens pour le traitement de la prééclampsie Download PDF

Info

Publication number
WO2016083623A1
WO2016083623A1 PCT/EP2015/078107 EP2015078107W WO2016083623A1 WO 2016083623 A1 WO2016083623 A1 WO 2016083623A1 EP 2015078107 W EP2015078107 W EP 2015078107W WO 2016083623 A1 WO2016083623 A1 WO 2016083623A1
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
modified
nucleotides
group
lipid
Prior art date
Application number
PCT/EP2015/078107
Other languages
English (en)
Inventor
Michael Kahn
Oliver Keil
Jorg Kaufmann
Ute SCHAEPER
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of WO2016083623A1 publication Critical patent/WO2016083623A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Definitions

  • the present invention is related to a lipid composition useful in the delivery of a pharmaceutically active agent to placenta of a female mammal, preferably a pregnant woman, and a double-stranded nucleic acid suitable to inhibit the expression of soluble VEGF receptor 1 (sFltl) and uses thereof.
  • a pharmaceutically active agent to placenta of a female mammal, preferably a pregnant woman
  • a double-stranded nucleic acid suitable to inhibit the expression of soluble VEGF receptor 1 (sFltl) and uses thereof.
  • VEGF-VEGF receptor (VEGFR) system has been shown to play central roles not only in physiological angiogenesis, but also in
  • VEGF-inhibitor sFlt-1
  • VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment, and a tyrosine kinase (TK) domain within the cytoplasmic domain.
  • RTKs receptor tyrosine kinases
  • Ig immunoglobulin
  • TK tyrosine kinase
  • This protein binds to VEGFR- A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells, placental trophoblast cells and peripheral blood monocytes.
  • Isoforms include a full-length transmembrane receptor iso form and shortened, soluble iso forms.
  • the soluble isoforms are associated with the onset of pre-eclampsia.
  • sFlt-1 is abnormally overexpressed in the placenta of preeclampsia patients, resulting in the major symptoms of the disease due to abnormal trapping of VEGFs.
  • FLT1 genes involvement in human disease may include cancer cell survival, proliferation, migration, and invasion, and tumor angiogenesis and metastasis. It may contribute to cancer pathogenesis by promoting inflammatory responses and recruitment of tumor-infiltrating macrophages.
  • soluble isoforms may be a cause of preeclampsia.
  • Pre-eclampsia is the most common hypertensive disease of pregnancy. About 5-8% of pregnancies are affected and pre-eclampsia accounts for 18% of maternal death in the USA associated with adverse fetal outcome.
  • Clinical parameters of pre-eclampsia are hypertension and proteinuria with an onset during week 20 of pregnancy. Mild and severe forms of preeclampsia can be distinguished.
  • Mild form of pre-eclampsia is characterized by > 140 mmHg systolic or 90 mm diastolic blood pressure and 300 mg proteinuria over 24h; severe forms of pre-eclampsia are characterized by more severe blood pressure and/or additional end organ dysfunction, i.e. HELLP (which is an acronym for hemolysis, elevated liver enzymes, low platelets), cerebral and visual disturbances, pulmonary edema, and eclampsia which is characterized by symptoms of preeclampsia plus seizures.
  • HELLP which is an acronym for hemolysis, elevated liver enzymes, low platelets
  • cerebral and visual disturbances pulmonary edema
  • eclampsia which is characterized by symptoms of preeclampsia plus seizures.
  • Treatment options are observation or delivery.
  • the delivery vehicle used in the delivery of the pharmaceutically active agent is to discriminate between the maternal tissue and the fetal tissue and more specifically is to avoid passage of the pharmaceutically active agent from the maternal organism to which the pharmaceutically active agent is administered, to the fetal organism.
  • the present invention addresses these unmet needs through discovery of lipid compositions and its use.
  • the present invention relates to a lipid compositions for use in a method of treating a disease, for delivering a pharmaceutically active agent to placenta of a female mammal, for use in a method for diagnosing a disease and for delivering a diagnostic agent to placenta of a female mammal.
  • the present invention also related to a short interfering RNA (siRNA) and a composition comprising such siRNA, wherein the siRNA is directed to an expressed RNA transcript of soluble VEGF receptor 1, sFltl (sometimes referred to as a "target nucleic acid” herein) and compositions thereof.
  • siRNA molecules can be used in the treatment of a variety of diseases and disorders where reduced expression of sFltl gene product is desirable, and in the treatment of pre-eclampsia in particular.
  • the siRNAs can be isolated siRNAs, chemically synthesized, modified in any number of ways by substitution, deletion, insertion or alteration. Modifications may include chemical modification of the sugar moiety or the bases or the phosphodiester bonds.
  • Fig. 1 is a summary of siRNA molecules tested in vitro for inhibition of sFltl target gene expression; nucleotides with 2'-0-methyl are marked bold; nucleotides with 2'-F are underlined.
  • Fig. 2 is a bar diagram showing the efficacy of different Fltl and sFltl -specific siRNA molecules on human sFltsl mRNA degradation in human umbilical vein endothelial cells (HuVeCs); knock-down of human sFltl mRNA is normalized relative to untreated HuVeCs and luciferase-specific siRNA being used as negative controls.
  • Fig. 3 is a bar diagram showing siRNA distribution in maternal liver, placenta, maternal lung and embryo upon delivery of siRNA by mean of AtuPLEX in pregnant mice (E13.5) 1 hour post treatment.
  • Fig. 4 represents microphotographs of mouse placenta (El 3.5) taken 1 hour after treatment with a lipoplex composition comprising AtuPLEX and Cy3 labeled siRNA; Cy3 labeled siRNA is depicted in red is detectable in vessels of the labyrinth layer.
  • Fig. 5 represents microphotographs of mouse placenta (El 3.5) taken 1 hour after treatment with a lipoplex composition comprising AtuPLEX and Cy3 labeled siRNA; the left microphotograph shows localization of Cy3 labeled siRNA in maternal, but not fetal vessels of the labyrinth layer; the right microphotograph shows part of the placenta with part of the umbilichord, whereCy3 labeled siRNA staining is lacking.
  • Fig. 6 A - B is a summary outlining the experimental set-up for determining target gene inhibition in mice using different siRNA molecules targeting either sFltl or PKN3 and different delivery systems (AtuPLEX and DACC10).
  • Fig. 7 A - F is a compilation of various bar diagram showing sFltl and PKN3 target gene expression in lungs of pregnant mice treated with either AtuPLEX or DACC10 as delivery vehicle.
  • PTEN expression is a house keeping gene. Its expression is not changes by AtuPLEX of DACC10 treatment.
  • Fig. 8 A - F is a compilation of various bar diagram showing sFltl and PKN3 target gene expression in placenta of pregnant mice treated with either AtuPLEX or DACC10 as delivery vehicle.
  • PTEN expression is a house keeping gene. Its expression is not changes by AtuPLEX of DACC10 treatment.
  • Fig. 9 A- C shows that AtuPLEX delivers siRNA to maternal and placental tissue
  • A Female Sprague-Dawley rats were treated at day 18 of gestation with 1.4 mg/kg AtuPLEX slRNACy3 . 1 hour and 4 hours after treatment maternal tissues (liver, lung, Li- heparin blood, placenta and mesometrial triangle (B)) were collected and siRNA concentrations in these tissues were determined by quantitative capture probe ELISA assay (Fehring et al, 2014).
  • Fig. 10 A - D shows that AtuPLEX prepared with Cy3-labeled siRNA delivers siRNA to the spongio-trophoblast layer of the placenta.
  • Fig. 11 - AtuPLEX does not delivery siRNA to tissues of the fetus (fetal lung or fetal liver): Rats at dl8 of gestation were treated with 1.4 mg/kg AtuPLEX slRNA ⁇ CY3 or sucrose solution as vehicle control by i.v. bolus application. 1 hour and 4 hours after treatment tissues were collected and processed for paraffin embedding and histology. CY3-labeled siRNA was detected in sinusoids of maternal liver tissue, but not in foetal lung or foetal liver tissues (left and middle panel, respectively) by fluorescent microscopy.
  • Fig. 12 Rats transgenic for human renin and human angiotensinogen as model for gestational hypertension.
  • Female rats transgenic for human angiotensinogen are mated with rats transgenic for human renin. During pregnancy, these rats develop high blood pressure, albuminuria and intrauterine growth reduction (IUGR).
  • IUGR intrauterine growth reduction
  • Fig. 13 AtuPLEX reduces sFLTl expression in lung tissue of the mother and in placental tissue.
  • Female rats transgenic for human angiotensinogen were mated with male transgenic rats for human renin. They received five treatments of either sucrose solution as vehicle control or AtuPLEX slRNAsFLT1"r8 siRNA, AtuPLEX ctrsiRNA1 or AtuPLEX ctrsiRNA2 at the time points indicated in (A).
  • sucrose solution as vehicle control
  • AtuPLEX slRNAsFLT1"r8 siRNA AtuPLEX ctrsiRNA1 or AtuPLEX ctrsiRNA2
  • Fig. 14 A -D shows that AtuPLEX siRNAsFLTl r8 reduces blood pressure in rat model of preeclampsia.
  • MAP arterial blood pressure
  • DBP diastolic blood pressure
  • systolic blood pressure increases beginning at day 13 of gestation. This elevation of blood pressure is reduced by repeated treatments with AtuPLEX (A,B) (see Figure.6A for treatment schedule).
  • Heart rate is not affected by AtuPLEX siRNAsFLT1" r8 compared to control groups treated with AtuPLEX ctr slRNA2 or sucrose as vehicle control (D) (mean ⁇ SEM).
  • Fig. 15 A - C - shows that no adverse effects by AtuPLEX concerning the wellbeing of the mother.
  • the maternal body weight (A), motor activity (B) or proteinuria (C) are not affected by repeated treatments with AtuPLEX.
  • Each dot depicts measurement of individual rats.
  • Fig. 16 A - B shows that the weight of the uteroplacental units, foetal weight or uteroplacental unit to fetus weight ratio is not adversely affected by repeated treatments with AtuPLEX siRNAsFLTl r8 or AtuPLEX ctr siRNA 2 ⁇ Depicted are individual values. B: There are fewer small embryos in the AtuPLEX slRNAsFLT_r8 treatment group.
  • the lowest 10% percentiles of the foetal weights are 2.12 g for the vehicle group, but 2.4 g for the the AtuPLEX siRNAsFLT ⁇ r8 treatment group (*p ⁇ 0.05; one-way ANOVA with Tukey's post hoc; ***p ⁇ 0.001, Kruskal- Wallis test with Dunn's post hoc mean ⁇ SEM).
  • Fig. 17 A - C shows that treatment with AtuPLEX does not enhance intrauterine growth reduction (IUGR).
  • IUGR intrauterine growth reduction
  • Foetal brain weights (A), foetal liver weights (B) and the ratio of foetal brain to fetal liver weights are depicted (C).
  • Fig. 18 A - C Fetal brain weights (A), fetal liver weights (B) and the ratio of foetal brain to fetal liver weights are depicted (C). Treatment with AtuPLEX does not enhance intrauterine growth reduction.
  • SEQ ID NOs: 1 to 22 are strands of different siRNAs targeting human sFltl .
  • SEQ ID NO: 25 is the mRNA sequence encoding human sFltl . This sequence has been taken from GenBank Accession number EU368830.1 which is incorporated herein by reference in its entirety. SEQ ID Nos: 23-24, 26-45 and 50-51 are strands of different siRNAs targeting
  • SEQ ID NOs: 46 and 47 are strands of an siRNA targeting CD31.
  • SEQ ID NOs: 48 and 49 are strands of an siRNA targeting luciferase.
  • SEQ ID NO. 52 - 59 are furhter strands of different siRNAs targeting human sFltl
  • SEQ ID NO. 60 - 65 are DNA primers in Example 7
  • SEQ ID NO. 25 mRNA sequence encoding human sFltl auggucagcu acugggacac cgggguccug cugugcgcgc ugcucagcug ucugcuucuc acaggaucua guucagguuc aaaauuaaa gauccugaac ugaguuuaaa aggcacccag cacaucaugc aagcaggcca gacacugcau cuccaaugca ggggggaagc agcccauaaa uggucuuugc cugaaauggu gaguaaggaa agcgaaaggc ugagcauaac uaaaucugcc uguggaagaa auggcaaaca auucugcagu acuuuaaccu ugaacacagc ucaagcaaac cacacuggcu ucuacagcua
  • lipid composition comprising a first lipid component and wherein the first lipid component is a compound according to formula (I),
  • Ri and R 2 are each and independently selected from the group comprising alkyl and alkenyl; n is any integer between 1 and 4;
  • R 3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II),
  • m is any integer from 1 to 3, wherein the NH 3 is optionally absent, and harmaceutically acceptable anion, in its various embodiments described herein, is effective in delivering a pharmaceutically active agent in a female mammal, preferably a pregnant female mammal and more preferably a pregnant woman, i.e. pregnant female human being, to the placenta but does not allow such pharmaceutically active agent to pass-over into the fetal organism.
  • the pharmaceutically active agent delivered by said lipid composition is prevented from being delivered to the fetal organism in the pregnant female mammal.
  • the pharmaceutically active agent is a nucleic acid, preferably an oligonucleotide such as an siRNA, which forms a lipoplex together with one or more of the lipid components of the lipid composition.
  • the lipid composition as described herein is sometimes also referred to herein as "delivery vehicle” or delivery vehicle of the invention.
  • delivery vehicle or delivery vehicle of the invention.
  • the following one comprising the following lipid composition may be used as delivery vehicle in accordance with the invention:
  • the present invention relates in a further aspect to compositions comprising short interfering RNA (siRNA) directed to an expressed RNA transcript of sFltl (sometimes referred to as a "target nucleic acid” herein).
  • siRNA short interfering RNA
  • sFltl an expressed RNA transcript of sFltl
  • target nucleic acid RNA transcript of sFltl
  • siRNA of the invention are nucleic acid molecules comprising a double stranded or duplex region as also disclosed in the claims.
  • the present invention further relates to methods of using the siRNA compositions to reduce the expression level of sFltl .
  • the terms "silence” or “knock-down" when referring to gene expression means a reduction in gene expression.
  • the present invention further relates to processes for making the siRNA.
  • the target nucleic acid is an RNA expressed from a mammalian sFltl gene. In one embodiment, the target nucleic acid is an RNA expressed from mouse sFltl . In another embodiment, the target nucleic acid is an RNA expressed from human sFltl . In another embodiment, the target nucleic acid is a human sFltl mRNA. In another embodiment, the target nucleic acid is a human sFltl hnRNA. In another embodiment, the target nucleic acid is an mRNA comprising the sequence of SEQ ID NO: 25.
  • the siRNA of the present invention are suitable to inhibit the expression of sFltl .
  • the siRNA according to the present invention is, thus, suitable to trigger the RNA interference response resulting in the reduction of the sFltl mRNA in a mammalian cell.
  • the siRNA according to the present invention are further suitable to decrease the expression of sFltl protein by decreasing gene expression at the level of mRNA.
  • siRNA Design An siRNA of the present invention comprises two strands of a nucleic acid, a first, antisense strand and a second, sense strand.
  • the nucleic acid normally consists of ribonucleotides or modified ribonucleotides however; the nucleic acid may comprise deoxynucleotides (DNA) as described herein.
  • the siRNA further comprises a double- stranded nucleic acid portion or duplex region formed by all or a portion of the antisense strand and all or a portion of the sense strand.
  • the portion of the antisense strand forming the duplex region with the sense strand is the antisense strand duplex region or simply, the antisense duplex region, and the portion of the sense strand forming the duplex region with the antisense strand is the sense strand duplex region or simply, the sense duplex region.
  • the duplex region is defined as beginning with the first base pair formed between the antisense strand and the sense strand and ending with the last base pair formed between the antisense strand and the sense strand, inclusive.
  • the portion of the siRNA on either side of the duplex region is the flanking regions.
  • the portion of the antisense strand on either side of the antisense duplex region is the antisense flanking regions.
  • the portion of the antisense strand 5' to the antisense duplex region is the antisense 5' flanking region.
  • the portion of the antisense strand 5' to the antisense duplex region is the antisense 3' flanking region.
  • the portion of the sense strand on either side of the sense duplex region is the sense flanking regions.
  • the portion of the sense strand 5 ' to the sense duplex region is the sense 5' flanking region.
  • the portion of the sense strand 5' to the sense duplex region is the sense 3' flanking region.
  • the antisense duplex region and the sense duplex region may be fully complementary and are at least partially complementary to each other.
  • Such complementarity is based on Watson-Crick base pairing (i.e., A:U and G:C base pairing).
  • A:U and G:C base pairing i.e., A:U and G:C base pairing.
  • the antisense and sense strands must be able to hybridize under physiological conditions.
  • the complementarity between the antisense strand and sense strand is perfect (no nucleotide mismatches or additional/deleted nucleotides in either strand).
  • the complementarity between the antisense duplex region and sense duplex region is perfect (no nucleotide mismatches or additional/deleted nucleotides in the duplex region of either strand).
  • the complementarity between the antisense duplex region and the sense duplex region is not perfect.
  • the identity between the antisense duplex region and the complementary sequence of the sense duplex region is selected from the group consisting of at least 75%, 80%>, 85%, 90% and 95%>; wherein a siRNA comprising the antisense duplex region and the sense duplex region is suitable for reducing expression of sFltl
  • the siRNA, wherein the identity between the antisense duplex region and complementary sequence of the sense duplex region is selected from the group consisting of at least 75%, 80%>, 85%, 90% and 95% is able to reduce expression of sFltl by at least 25%, 50% or 75% of a comparative siRNA having a duplex region with perfect identity between the antisense duplex region and the sense duplex region.
  • the term "comparative siRNA” is a siRNA that is identical to the siRNA to which it is being compared, except for the specified difference
  • RNAi using siRNA involves the formation of a duplex region between all or a portion of the antisense strand and a portion of the target nucleic acid.
  • the portion of the target nucleic acid that forms a duplex region with the antisense strand defined as beginning with the first base pair formed between the antisense strand and the target sequence and ending with the last base pair formed between the antisense strand and the target sequence, inclusive, is the target nucleic acid sequence or simply, target sequence.
  • the duplex region formed between the antisense strand and the sense strand may, but need not be the same as the duplex region formed between the antisense strand and the target sequence. That is, the sense strand may have a sequence different from the target sequence however; the antisense strand must be able to form a duplex structure with both the sense strand and the target sequence.
  • the complementarity between the antisense strand and the target sequence is perfect (no nucleotide mismatches or additional/deleted nucleotides in either nucleic acid).
  • the complementarity between the antisense duplex region (the portion of the antisense strand forming a duplex region with the sense strand) and the target sequence is perfect (no nucleotide mismatches or additional/deleted nucleotides in either nucleic acid).
  • the complementarity between the antisense duplex region and the target sequence is not perfect.
  • the identity between the antisense duplex region and the complementary sequence of the target sequence is selected from the group consisting of at least 75%, 80%, 85%, 90% or 95%, wherein a siRNA comprising the antisense duplex region is suitable for reducing expression of sFltl .
  • the siRNA wherein the identity between the antisense duplex region and complementary sequence of the target sequence is selected from the group consisting of at least 75%, 80%, 85%, 90% and 95%, is able to reduce expression of sFltl by at least 25%, 50% or 75% of a comparative siRNA with perfect identity to the antisense strand and target sequence.
  • the siRNA of the invention comprises a duplex region wherein the antisense duplex region has a number of nucleotides selected from the group consisting of 1, 2, 3, 4 and 5 that are not base-paired to a nucleotide in the sense duplex region, and wherein said siRNA is suitable for reducing expression of sFltl .
  • Lack of base- pairing is due to either lack of complementarity between bases (i.e., no Watson-Crick base pairing) or because there is no corresponding nucleotide on either the antisense duplex region or the sense duplex region such that a bulge is created.
  • a siRNA comprising an antisense duplex region having a number of nucleotides selected from the group consisting of 1, 2, 3, 4 and 5 that are not base-paired to the sense duplex region, is able to reduce expression of sFltl by at least 25%, 50%, 75% of a comparative siRNA wherein all nucleotides of said antisense duplex region are base paired with all nucleotides of said sense duplex region.
  • the antisense strand has a number of nucleotides selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 that do not base-pair to the sense strand, and wherein a siRNA comprising said antisense strand is suitable for reducing expression of sFltl .
  • Lack of complementarity is due to either lack of complementarity between bases or because there is no corresponding nucleotide on either the antisense strand or the sense strand.
  • the lack of a corresponding nucleotide results in either a single-stranded overhang or a bulge (if in the duplex region), in either the antisense strand or the sense strand.
  • a siRNA comprising an antisense strand having a number of nucleotides selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 that do not base pair to the sense strand, is able to reduce expression of sFltl by at least 25%, 50%, 75% of a comparative siRNA wherein all nucleotides of said antisense strand are complementary to all nucleotides of the sense strand.
  • a siRNA comprising an antisense strand having a number of nucleotides selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 that are mismatched to the target sequence, is able to reduce expression of sFltl by at least 25%, 50%, 75% of a comparative siRNA wherein all nucleotides of said antisense strand are complementary to all nucleotides of said sense strand. In another embodiment, all of the mismatched nucleotides are outside the duplex region.
  • the antisense duplex region has a number of nucleotides selected from 1, 2, 3, 4 or 5 that do not base-pair to the sense duplex region, and wherein a siRNA comprising said antisense duplex region is suitable for reducing expression of sFltl .
  • Lack of complementarity is due to either lack of complementarity between bases or because there is no corresponding nucleotide on either the antisense duplex region or the sense duplex region such that a bulge in created in either the antisense duplex region or the sense duplex region.
  • a siRNA comprising an antisense duplex region having a number of nucleotides selected from the group consisting of 1, 2, 3, 4 and 5 that do not base pair to the sense duplex region, is able to reduce expression of sFltl by at least 25%, 50%, 75% of a comparative siRNA wherein all nucleotides of said antisense duplex region are complementary to all of the nucleotides of said sense duplex region.
  • the antisense strand has a number of nucleotides selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 that do not base-pair to the target sequence, and wherein a siRNA comprising said antisense strand is suitable for reducing expression of sFltl .
  • Lack of complementarity is due to either lack of complementarity between bases or because there is no corresponding nucleotide on either the antisense strand or the target sequence. The lack of a corresponding nucleotide results in a bulge in either the antisense strand or the target sequence.
  • a siRNA comprising an antisense strand having a number of nucleotides selected from 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 do not base pair to the target sequence, is able to reduce expression of sFltl by at least 25%, 50%, 75% of a comparative siRNA wherein all nucleotides of said antisense strand are complementary to all nucleotides of said target sequence.
  • a siRNA comprising an antisense strand having a number of nucleotides selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 that are mismatched to the target sequence, is able to reduce expression of sFltl by at least 25%, 50% or 75% of a comparative siRNA wherein all nucleotides of said antisense strand are complementary to all nucleotides of said target sequence.
  • the complementarity between an antisense duplex region and both a sense duplex region and a target sequence of an siRNA is such that the antisense duplex region and the sense duplex region or the target sequence hybridize to one another under physiological conditions (37°C in a physiological buffer) and the siRNA is suitable for reducing expression of sFltl .
  • the siRNA comprising an antisense duplex region that hybridizes to a sense duplex region and a target sequence under physiological conditions is able to reduce expression of sFltl by at least 25%, 50%, 75% of a comparative siRNA with perfect complementarity between the antisense strand and target sequence.
  • the complementarity between an antisense duplex region and a sense duplex region of a siRNA is such that the antisense duplex region and sense duplex region hybridize under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 70°C, and is suitable for reducing expression of sFltl .
  • the siRNA comprising an antisense duplex region and a sense duplex region that hybridize to one another under the conditions 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 70°C, is able to reduce expression of sFltl by at least 25%, 50%, 75% of a comparative siRNA with perfect complementarity between the antisense duplex region and sense duplex region.
  • the complementarity between an antisense strand of a siRNA and a target sequence is such that the antisense strand and target sequence hybridize under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 70°C and wherein the siRNA is suitable for reducing expression of sFltl .
  • the siRNA comprising an antisense strand that hybridizes to the target sequence under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 70°C, is able to reduce expression of sFltl by at least 25%, 50%, 75% of a comparative siRNA with perfect complementarity between the antisense strand and the target sequence.
  • RNA interference is observed using long nucleic acid molecules comprising several dozen or hundreds of base pairs, although shorter RNAi molecules are generally preferred.
  • the length of the siRNA duplex region is selected from the group consisting of about 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, 19 to 23, 20 to 25, 20 to 24, 21 to 25 and 21 to 24 base pairs. In one embodiment, the length of the siRNA duplex region is selected from the group consisting of about 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, 19 to 23, 20 to 25, 20 to 24, 21 to 25 and 21 to 24 consecutive base pairs.
  • the length of the siRNA duplex region is selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 base pairs. In another embodiment, the length of the siRNA duplex region is selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 consecutive base pairs.
  • the length of the antisense strand is selected from the group consisting of about 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, 19 to 23, 20 to 25, 20 to 24, 21 to 25 and 21 to 24 nucleotides.
  • the length of the antisense stand is selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 nucleotides.
  • the length of the sense strand is selected from the group consisting of about 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, 19 to 23, 20 to 25, 20 to 24, 21 to 25 and 21 to 24 nucleotides.
  • the length of the sense stand is selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 nucleotides.
  • the length of the antisense strand and the length of the sense strand are independently selected from the group consisting of about 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, 19 to 23, 20 to 25, 20 to 24, 21 to 25 and 21 to 24 nucleotides.
  • the length of the antisense strand and the length of the sense stand are independently selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 nucleotides.
  • the antisense strand and the sense strand are equal in length.
  • the antisense strand and the sense stand are equal in length, wherein the length is selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 nucleotides.
  • the length of the antisense strand is selected from the group consisting of about 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, 19 to 23, 20 to 25, 20 to 24, 21 to 25 and 21 to 24 nucleotides, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23, preferably SEQ ID NOs: 1, 3, or 5.
  • the length of the antisense strand is selected from the group consisting of about 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 nucleotides, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23, preferably SEQ ID NOs: 1, 3, or 5.
  • the length of the sense strand is selected from the group consisting of about 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to
  • the sense strand comprises the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, preferably SEQ ID NOs: 2, 4 or 6..
  • the length of the sense strand is selected from the group consisting of about 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 nucleotides, wherein the sense strand comprises the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, preferably SEQ ID NOs: 2, 4 or 6.
  • the length of the antisense strand and the length of the sense strand are independently selected from the group consisting of about 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, 19 to 23, 20 to 25, 20 to 24, 21 to 25 and 21 to 24 nucleotides, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NOs: 1 , 3, 5, 7, 9, 11 , 13, 15, 17, 19, 21 or 23, preferably SEQ ID NOs: 1, 3, or 5, and wherein the sense strand comprises the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, preferably SEQ ID NOs: 2, 4 or 6.
  • the length of the antisense strand and the length of the sense stand are independently selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
  • the antisense strand comprises the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13 or 15, preferably SEQ ID NOs: 1, 3, 5, or 7, and wherein the sense strand comprises the nucleotide sequence SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14 or 16, preferably SEQ ID NOs: 2, 4, 6, or 8.
  • the antisense strand and the sense strand are equal in length, wherein the antisense strand comprises the nucleotide sequence SEQ ID NOs: 1 , 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23, preferably SEQ ID NOs: 1, 3, or 5, and wherein the sense strand comprises the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, preferably SEQ ID NOs: 2, 4 or 6.
  • the antisense strand and the sense stand are equal in length, wherein the length is selected from the group consisting of 16 to 35, 16 to 30, 17 to 35, 17 to 30, 17 to 25, 17 to 24, 18 to 29, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, 19 to 23, 20 to 25, 20 to 24, 21 to 25 and 21 to 24 nucleotides, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23, preferably SEQ ID NOs: 1, 3, or 5, and wherein the sense strand comprises the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, preferably SEQ ID NOs: 2, 4 or 6.
  • the antisense strand and the sense stand are equal in length, wherein the length is selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 nucleotides, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NOs: 1 , 3, 5, 7, 9, 11 , 13, 15, 17, 19, 21 or 23, preferably SEQ ID NOs: 1, 3, or 5, and wherein the sense strand comprises the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, preferably SEQ ID NOs: 2, 4 or 6.
  • Certain embodiments provide for antisense and sense strand combinations (identified by SEQ ID NO:): 1 and 2; 3 and 4; and 5 and 6.
  • the siRNA of the present invention may comprise an overhang or be blunt ended.
  • An "overhang” as used herein has its normal and customary meaning in the art, i.e., a single stranded portion of a nucleic acid that extends beyond the terminal nucleotide of a complementary strand in a double strand nucleic acid.
  • the term "blunt end” includes double stranded nucleic acid whereby both strands terminate at the same position, regardless of whether the terminal nucleotide(s) are base paired.
  • the terminal nucleotide of an antisense strand and a sense strand at a blunt end are base paired.
  • the terminal nucleotide of a antisense strand and a sense strand at a blunt end are not paired. In another embodiment, the terminal two nucleotides of an antisense strand and a sense strand at a blunt end are base paired. In another embodiment, the terminal two nucleotides of an antisense strand and a sense strand at a blunt end are not paired.
  • the siRNA has an overhang at one end and a blunt end at the other. In another embodiment, the siRNA has an overhang at both ends. In another embodiment, the siRNA is blunt ended at both ends. In one embodiment, the siRNA is blunt ended at one end. In another embodiment, the siRNA is blunt ended at the end with the 5 '- end of the antisense strand and the 3 '-end of the sense strand. In another embodiment, the siRNA is blunt ended at the end with the 3 '-end of the antisense strand and the 5 '-end of the sense strand. In another embodiment, the siRNA is blunt ended at both ends.
  • the siRNA comprises an overhang at a 3'- or 5 '-end. In one embodiment, the siRNA has a 3 '-overhang on the antisense strand. In another embodiment, the siRNA has a 3 '-overhang on the sense strand. In another embodiment, the siRNA has a 5'- overhang on the antisense strand. In another embodiment, the siRNA has a 5 '-overhang on the sense strand. In another embodiment, the siRNA has an overhang at both the 5 '-end and 3'- end of the antisense stand. In another embodiment, the siRNA has an overhang at both the 5'- end and 3 '-end of the sense stand.
  • the siRNA has a 5' overhang on the antisense stand and a 3 ' overhang on the sense strand. In another embodiment, the siRNA has a 3' overhang on the antisense stand and a 5' overhang on the sense strand. In another embodiment, the siRNA has a 3' overhang on the antisense stand and a 3' overhang on the sense strand. In another embodiment, the siRNA has a 5' overhang on the antisense stand and a 5 ' overhang on the sense strand.
  • the overhang at the 3 '-end of the antisense strand has a length selected from the group consisting of 1, 2, 3, 4 and 5 nucleotides. In one embodiment, the overhang at the 3 '-end of the sense strand has a length selected from the group consisting of 1, 2, 3, 4 and 5 nucleotides. In one embodiment, the overhang at the 5 '-end of the antisense strand has a length selected from the group consisting of 1, 2, 3, 4 and 5 nucleotides. In one embodiment, the overhang at the 5 '-end of the sense strand has a length selected from the group consisting of 1, 2, 3, 4 and 5 nucleotides.
  • the siRNA according to the invention are a ribonucleic acid or a modified ribonucleic acid.
  • Chemical modifications of the siRNA of the present invention provides a powerful tool in overcoming potential limitations including, but not limited to, in vitro and in vivo stability and bioavailability inherent to native RNA molecules. Chemically-modified siRNA can also minimize the possibility of activating interferon activity in humans. Chemical modification can further enhance the functional delivery of a siRNA to a target cell.
  • the modified siRNA of the present invention may comprise one or more chemically modified ribonucleotides of either or both of the antisense strand or the sense strand.
  • a ribonucleotide may comprise a chemical modification of the base, sugar or phosphate moieties.
  • a secondary aspect relates to modifications to a base moiety.
  • One or more nucleotides of a siRNA of the present invention may comprise a modified base or a nucleotide analogue.
  • a "modified base” means a nucleotide base other than an adenine, guanine, cytosine or uracil at the ⁇ position.
  • the siRNA comprises at least one nucleotide comprising a modified base.
  • the modified base in on the antisense strand.
  • the modified base in on the sense strand.
  • the modified base is in the duplex region.
  • the modified base is outside the duplex region, i.e., in a single stranded region.
  • the modified base is on the antisense strand and is outside the duplex region.
  • the modified base is on the sense strand and is outside the duplex region.
  • the 3 '-terminal nucleotide of the antisense strand is a nucleotide with a modified base.
  • the 3 '-terminal nucleotide of the sense strand is nucleotide with a modified base.
  • the 5 '-terminal nucleotide of the antisense strand is nucleotide with a modified base.
  • the 5 '-terminal nucleotide of the sense strand is nucleotide with a modified base.
  • a siRNA has 1 modified base. In another embodiment, a siRNA has about 2-4 modified bases. In another embodiment, a siRNA has about 4-6 modified bases. In another embodiment, a siRNA has about 6-8 modified bases. In another embodiment, a siRNA has about 8-10 modified bases. In another embodiment, a siRNA has about 10-12 modified bases. In another embodiment, a siRNA has about 12-14 modified bases. In another embodiment, a siRNA has about 14-16 modified bases. In another embodiment, a siRNA has about 16-18 modified bases. In another embodiment, a siRNA has about 18-20 modified bases. In another embodiment, a siRNA has about 20-22 modified bases. In another embodiment, a siRNA has about 22-24 modified bases.
  • a siRNA has about 24-26 modified bases. In another embodiment, a siRNA has about 26-28 modified bases. In each case the siRNA comprising said modified bases retains at least 50% of its activity as compared to the same siRNA but without said modified bases.
  • the modified base is a purine. In another embodiment, the modified base is a pyrimidine. In another embodiment, at least half of the purines are modified. In another embodiment, at least half of the pyrimidines are modified. In another embodiment, all of the purines are modified. In another embodiment, all of the pyrimidines are modified.
  • the siRNA comprises a nucleotide comprising a modified base, wherein the base is selected from the group consisting of 2-aminoadenosine, 2,6- diaminopurine,inosine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidine (e.g., 5- methylcytidine), 5-alkyluridine (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine), 6- azapyrimidine, 6-alkylpyrimidine (e.g.
  • 6-methyluridine 6-methyluridine
  • propyne quesosine, 2-thiouridine, 4- thiouridine, wybutosine, wybutoxosine, 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 5 '-carboxymethylaminomethyl-2-thiouridine, 5 -carboxymethylaminomethyluridine, beta-D- galactosylqueosine, 1-methyladenosine, 1-methylinosine, 2,2-dimethylguanosine, 3- methylcytidine, 2-methyladenosine, 2-methylguanosine, N6-methyladenosine, 7- methylguanosine, 5-methoxyaminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5- methylcarbonylmethyluridine, 5-methyloxyuridine, 5-methyl-2-thiouridine, 2-methylthio-N6- isopentenyladenosine, beta-D-mannosy
  • a siRNA of the present invention comprises an abasic nucleotide.
  • abasic refers to moieties lacking a base or having other chemical groups in place of a base at the ⁇ position, for example a 3',3'-linked or 5',5'-linked deoxyabasic ribose derivative.
  • a nucleotide with a modified base does not include abasic nucleotides.
  • the siRNA comprises at least one abasic nucleotide.
  • the abasic nucleotide is on the antisense strand.
  • the abasic nucleotide is on the sense strand.
  • the abasic nucleotide is in the duplex region. In another embodiment, the abasic nucleotide is outside the duplex region. In another embodiment, the abasic nucleotide is on the antisense strand and is outside the duplex region. In another embodiment, the abasic nucleotide is on the sense strand and is outside the duplex region. In another embodiment, the 3 '-terminal nucleotide of the antisense strand is an abasic nucleotide. In another embodiment, the 3 '-terminal nucleotide of the sense strand is an abasic nucleotide.
  • the 5 '-terminal nucleotide of the antisense strand is an abasic nucleotide.
  • the 5 '-terminal nucleotide of the sense strand is an abasic nucleotide.
  • a siRNA has a number of abasic nucleotides selected from the group consisting of 1, 2, 3, 4, 5 and 6.
  • Modifications to sugar moiety Another secondary aspect relates to modifications to a sugar moiety.
  • One or more nucleotides of an siRNA of the present invention may comprise a modified ribose moiety.
  • Modifications at the 2'-position wherein the 2'-OH is substituted include the non- limiting examples selected from the group consisting of alkyl, substituted alkyl, alkaryl-, aralkyl-, -F, -CI, -Br, -CN, -CF3, -OCF3, -OCN, -O-alkyl, -S-alkyl, HS-alkyl-O, -O-alkenyl, -S-alkenyl, -N-alkenyl, -SO-alkyl, -alkyl-OSH, -alkyl-OH, -O-alkyl-OH, -O-alkyl-SH, -S- alkyl-OH, -S-alkyl-SH, -alkyl-S-alkyl, -alkyl-O-alkyl, -ON02, -N02, -N3, -NH2, alkylamino, dialkyla
  • LNA Locked nucleic acids
  • Preferred substitutents are 2'-0-methoxyethyl, 2'-0-CH3, 2'-0-allyl, 2'-C-allyl, and 2'-fluoro.
  • the siRNA comprises 1-5 2'-modified nucleotides. In another embodiment, the siRNA comprises 5-10 2'-modified nucleotides. In another embodiment, the siRNA comprises 15-20 2'-modified nucleotides. In another embodiment, the siRNA comprises 20-25 2'-modified nucleotides. In another embodiment, the siRNA comprises 25- 30 2 '-modified nucleotides.
  • the antisense strand comprises 1-2 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 2-4 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 4-6 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 6-8 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 8-10 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 10-12 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 12-14 2'-modified nucleotides.
  • the antisense strand comprises about 14-16 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 16-18 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 18-20 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 22-24 2'-modified nucleotides. In one embodiment, the antisense strand comprises about 24-26 2'-modified nucleotides.
  • the sense strand comprises 1-2 2'-modified nucleotides. In one embodiment, the sense strand comprises about 2-4 2'-modified nucleotides. In one embodiment, the sense strand comprises about 4-6 2'-modified nucleotides. In one embodiment, the sense strand comprises about 6-8 2'-modified nucleotides. In one embodiment, the sense strand comprises about 8-10 2'-modified nucleotides. In one embodiment, the sense strand comprises about 10-12 2'-modified nucleotides. In one embodiment, the sense strand comprises about 12-14 2'-modified nucleotides. In one embodiment, the sense strand comprises about 14-16 2'-modified nucleotides.
  • the sense strand comprises about 16-18 2'-modified nucleotides. In one embodiment, the sense strand comprises about 18-20 2'-modified nucleotides. In one embodiment, the sense strand comprises about 22-24 2'-modified nucleotides. In one embodiment, the sense strand comprises about 24-26 2'-modified nucleotides.
  • the siR A comprises 1-5 2'-0-CH3 modified nucleotides. In another embodiment, the siRNA comprises 5-10 2'-0-CH3 modified nucleotides. In another embodiment, the siRNA comprises 15-20 2'-0-CH3 modified nucleotides. In another embodiment, the siRNA comprises 20-25 2'-0-CH3 modified nucleotides. In another embodiment, the siRNA comprises 25-30 2'-0-CH3 modified nucleotides.
  • the antisense strand comprises 1-2 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 2-4 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 4-6 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 6-8 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 8-10 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 10-12 2'-0- CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 12-14 2'-0-CH3 modified nucleotides.
  • the antisense strand comprises about 14- 16 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 16-18 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 18-20 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 22-24 2'-0-CH3 modified nucleotides. In one embodiment, the antisense strand comprises about 24-26 2'-0-CH3 modified nucleotides.
  • the sense strand comprises 1-2 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 2-4 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 4-6 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 6-8 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 8-10 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 10-12 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 12-14 2'-0-CH3 modified nucleotides.
  • the sense strand comprises about 14-16 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 16-18 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 18-20 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 22-24 2'-0-CH3 modified nucleotides. In one embodiment, the sense strand comprises about 24-26 2'-0-CH3 modified nucleotides.
  • the siR A duplex region comprises 1-5 2'-0-CH3 modified nucleotides. In another embodiment, the siRNA duplex region comprises 5-10 2'-0-CH3 modified nucleotides. In another embodiment, the siRNA duplex region comprises 15-20 2'- 0-CH3 modified nucleotides. In another embodiment, the siRNA duplex region comprises 20-25 2'-0-CH3 modified nucleotides. In another embodiment, the siRNA duplex region comprises 25-30 2'-0-CH3 modified nucleotides.
  • the antisense duplex region comprises 1-2 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 2-4 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 4-6 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 6-8 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 8-10 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 10-12 2'-0-CH3 modified nucleotides.
  • the antisense duplex region comprises about 12-14 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 14-16 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 16-18 2'-0- CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 18-20 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 22-24 2'-0-CH3 modified nucleotides. In one embodiment, the antisense duplex region comprises about 24-26 2'-0-CH3 modified nucleotides.
  • the sense duplex region comprises 1-2 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 2-4 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 4-6 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 6-8 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 8-10 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 10-12 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 12-14 2'-0-CH3 modified nucleotides.
  • the sense duplex region comprises about 14-16 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 16-18 2'-0- CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 18-20 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 22-24 2'-0-CH3 modified nucleotides. In another embodiment, the sense duplex region comprises about 24-26 2'-0-CH3 modified nucleotides.
  • the siRNA comprises an antisense strand 19 nucleotides in length and a sense strand 19 nucleotides in length, wherein said antisense strand comprises 2'-0- CH3 modifications at nucleotides 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19, and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 2, 4, 6, 8, 10, 12 ,14, 16 and 18, wherein said antisense strand is numbered from 5 '-3' and said sense strand is numbered from 3 '-5'.
  • the siRNA comprises an antisense strand 20 nucleotides in length and a sense strand 20 nucleotides in length, wherein said antisense strand comprises 2'- 0-CH3 modifications at nucleotides 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19, and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 2, 4, 6, 8, 10, 12 ,14, 16, 18 and 20 wherein said antisense strand is numbered from 5 '-3' and said sense strand is numbered from 3 '-5'.
  • the siRNA comprises an antisense strand 21 nucleotides in length and a sense strand 21 nucleotides in length, wherein said antisense strand comprises 2'-0-CH3 modifications at nucleotides 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and 21, and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 2, 4, 6, 8,
  • the siRNA comprises an antisense strand 22 nucleotides in length and a sense strand 22 nucleotides in length, wherein said antisense strand comprises 2'-0-CH3 modifications at nucleotides 1 , 3, 5, 7, 9, 1 1, 13, 15, 17, 19 and 21 , and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 2, 4, 6, 8, 10, 12 ,14, 16, 18, 20 and 22, wherein said antisense strand is numbered from 5'-3 ' and said sense strand is numbered from 3 '-5'.
  • the siRNA comprises an antisense strand 23 nucleotides in length and a sense strand 23 nucleotides in length, wherein said antisense strand comprises 2'-0-CH3 modifications at nucleotides 1, 3, 5, 7, 9,
  • said sense strand comprises 2'-0-CH3 modifications at nucleotides 2, 4, 6, 8, 10, 12 ,14, 16, 18, 20 and 22 wherein said antisense strand is numbered from 5 '-3' and said sense strand is numbered from 3 '-5'.
  • the siRNA comprises an antisense strand 18-23 nucleotides in length and a sense strand 18-23 nucleotides in length, wherein said antisense strand comprises 2'-0-CH3 modifications at nucleotides 3, 5, 7, 9, 11, 13, 15 and 17, and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 4, 6, 8, 10, 12 ,14 and 16, wherein said antisense strand is numbered from 5 '-3' and said sense strand is numbered from 3 '-5' .
  • the siRNA comprises an antisense strand 18-23 nucleotides in length and a sense strand 18-23 nucleotides in length, wherein said antisense strand comprises 2'-0- CH3 modifications at nucleotides 5, 7, 9, 11, 13 and 15, and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 6, 8, 10, 12 and 14, wherein said antisense strand is numbered from 5 '-3' and said sense strand is numbered from 3 '-5'.
  • the siRNA comprises an antisense strand 18-23 nucleotides in length and a sense strand 18-23 nucleotides in length, wherein said antisense strand comprises 2'-0-CH3 modifications at nucleotides 7, 9, 11, 13 and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 8, 10 and 12, wherein said antisense strand is numbered from 5'- 3' and said sense strand is numbered from 3 '-5'.
  • the siRNA comprises an antisense strand 18-23 nucleotides in length and a sense strand 18-23 nucleotides in length, wherein said antisense strand comprises 2'-0-CH3 modifications at nucleotides 7, 9 and 11, and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 8, 10 and 12, wherein said antisense strand is numbered from 5'-3' and said sense strand is numbered from 3 '-5'.
  • the siRNA comprises an antisense strand 18-23 nucleotides in length and a sense strand 18-23 nucleotides in length, wherein said antisense strand comprises 2'-0-CH3 modifications at nucleotides 7 and 9, and wherein said sense strand comprises 2'-0-CH3 modifications at nucleotides 8 and 10, wherein said antisense strand is numbered from 5 '-3' and said sense strand is numbered from 3 '-5'.
  • the siRNA comprises an antisense strand 18-23 nucleotides in length and a sense strand 18-23 nucleotides in length, wherein said antisense strand comprises 2'-0- CH3 modifications at nucleotides 9 and 11, and wherein said sense strand comprises 2'-0- CH3 modifications at nucleotides 8 and 10, wherein said antisense strand is numbered from 5 '-3' and said sense strand is numbered from 3 '-5'.
  • the antisense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
  • the sense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
  • the antisense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
  • the sense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
  • the pyrimidine nucleotides in the antisense strand are 2'-0- methyl pyrimidine nucleotides.
  • purine nucleotides in the antisense strand are 2'-0- methyl purine nucleotides.
  • the pyrimidine nucleotides in the antisense strand are 2'- deoxy pyrimidine nucleotides.
  • the purine nucleotides in the antisense strand are 2'-deoxy purine nucleotides.
  • the pyrimidine nucleotides in the antisense strand are 2'- fluoro pyrimidine nucleotides.
  • the purine nucleotides in the antisense strand are 2'-fluoro purine nucleotides.
  • the pyrimidine nucleotides in the sense strand are 2'-0-methyl pyrimidine nucleotides.
  • purine nucleotides in the sense strand are 2'-0-methyl purine nucleotides.
  • the pyrimidine nucleotides in the sense strand are 2'-deoxy pyrimidine nucleotides.
  • the purine nucleotides in the sense strand are 2'-deoxy purine nucleotides.
  • the pyrimidine nucleotides in the sense strand are 2'-fluoro pyrimidine nucleotides.
  • the purine nucleotides in the sense strand are 2'-fluoro purine nucleotides.
  • the pyrimidine nucleotides in the antisense duplex region are 2'-0-methyl pyrimidine nucleotides.
  • purine nucleotides in the antisense duplex region are 2'- O-methyl purine nucleotides.
  • the pyrimidine nucleotides in the antisense duplex region are 2'-deoxy pyrimidine nucleotides.
  • the purine nucleotides in the antisense duplex region are 2'- deoxy purine nucleotides.
  • the pyrimidine nucleotides in the antisense duplex region are 2'-fluoro pyrimidine nucleotides.
  • the purine nucleotides in the antisense duplex region are 2'- fluoro purine nucleotides.
  • the pyrimidine nucleotides in the sense duplex region are 2'- O-methyl pyrimidine nucleotides.
  • purine nucleotides in the sense duplex region are 2'-0- methyl purine nucleotides.
  • the pyrimidine nucleotides in the sense duplex region are 2'- deoxy pyrimidine nucleotides.
  • the purine nucleotides in the sense duplex region are 2'-deoxy purine nucleotides.
  • the pyrimidine nucleotides in the sense duplex region are 2'- fluoro pyrimidine nucleotides.
  • the purine nucleotides in the sense duplex region are 2'-fluoro purine nucleotides.
  • the pyrimidine nucleotides in the antisense duplex flanking regions are 2'-0-methyl pyrimidine nucleotides.
  • purine nucleotides in the antisense duplex flanking regions are 2'-0-methyl purine nucleotides.
  • the pyrimidine nucleotides in the antisense duplex flanking regions are 2 '-deoxy pyrimidine nucleotides.
  • the purine nucleotides in the antisense duplex flanking regions are 2'-deoxy purine nucleotides.
  • the pyrimidine nucleotides in the antisense duplex flanking regions are 2'-fluoro pyrimidine nucleotides.
  • the purine nucleotides in the antisense duplex flanking regions are 2'-fluoro purine nucleotides.
  • the pyrimidine nucleotides in the sense duplex flanking regions are 2'-0-methyl pyrimidine nucleotides.
  • the purine nucleotides in the sense duplex flanking regions are 2'-0-methyl purine nucleotides.
  • the pyrimidine nucleotides in the sense duplex flanking regions are 2 '-deoxy pyrimidine nucleotides.
  • the purine nucleotides in the sense duplex flanking regions are 2 '-deoxy purine nucleotides.
  • the pyrimidine nucleotides in the sense duplex flanking regions are 2'-fluoro pyrimidine nucleotides.
  • the purine nucleotides in the sense duplex flanking regions are 2'-fluoro purine nucleotides.
  • the antisense duplex region comprises a plurality of groups of modified nucleotides, referred to herein as "modified groups", wherein each modified group consists of one or more identically modified nucleotides, wherein each modified group is flanked on one or both sides by a second group of nucleotides, referred to herein as “flanking groups", wherein each said flanking group consists of one or more nucleotides that are either unmodified or modified in a manner different from the nucleotides of said modified group.
  • each modified group in the antisense duplex region is identical, i.e., each modified group consists of an equal number of identically modified nucleotides.
  • each flanking group has an equal number of nucleotide. In another embodiment, each flanking group is identical. In another embodiment, the nucleotides of said modified groups in the antisense duplex region comprise a modified base. In another embodiment, the nucleotides of said modified groups comprise a modified phosphate backbone. In another embodiment, the nucleotides of said modified groups comprise a modified 2' position.
  • the sense duplex region comprises a plurality of groups of modified groups, wherein each modified group consists of one or more identically modified nucleotides, wherein each modified group is flanked on one or both sides by a flanking group, wherein each said flanking group consists of one or more nucleotides that are either unmodified or modified in a manner different from the nucleotides of said modified group.
  • each modified group in the sense duplex region is identical.
  • each flanking group has an equal number of nucleotides.
  • each flanking group is identical.
  • the nucleotides of said modified groups in the sense duplex region comprise a modified base.
  • the nucleotides of said modified groups comprise a modified phosphate backbone.
  • the nucleotides of said modified groups comprise a modified 2' position.
  • the antisense duplex region and the sense duplex region each comprise a plurality of modified groups, wherein each modified group consists of one or more identically modified nucleotides, wherein each modified group is flanked on one or both sides by a flanking group, wherein each said flanking group consists of one or more nucleotides that are either unmodified or modified in a manner different from the nucleotides of said modified group.
  • each modified group in the antisense duplex region and the sense duplex region are identical.
  • each flanking group in the antisense duplex region and the sense duplex region each have an equal number of nucleotides.
  • each flanking group in the antisense duplex region and in the sense duplex region are identical.
  • the nucleotides of said modified groups in the antisense duplex region and the sense duplex region each comprise the same modified groups and the same flanking groups.
  • the nucleotides of said modified groups in the antisense duplex region and the sense duplex region each comprise a modified base.
  • the nucleotides of said modified groups in the antisense duplex region and the sense duplex region each comprise a modified phosphate backbone.
  • the nucleotides of said modified groups in the antisense duplex region and the sense duplex region each comprise a modified 2' position.
  • the antisense strand comprises a plurality of groups of modified nucleotides, referred to herein as "modified groups", wherein each modified group consists of one or more identically modified nucleotides, wherein each modified group is flanked on one or both sides by a second group of nucleotides, referred to herein as “flanking groups", wherein each said flanking group consists of one or more nucleotides that are either unmodified or modified in a manner different from the nucleotides of said modified group.
  • each modified group in the antisense strand is identical, i.e., each modified group consists of an equal number of identically modified nucleotides.
  • each flanking group has an equal number of nucleotide. In another embodiment, each flanking group is identical. In another embodiment, the nucleotides of said modified groups in the antisense strand comprise a modified base. In another embodiment, the nucleotides of said modified groups comprise a modified phosphate backbone. In another embodiment, the nucleotides of said modified groups comprise a modified 2' position.
  • the sense strand comprises a plurality of groups of modified groups, wherein each modified group consists of one or more identically modified nucleotides, wherein each modified group is flanked on one or both sides by a flanking group, wherein each said flanking group consists of one or more nucleotides that are either unmodified or modified in a manner different from the nucleotides of said modified group.
  • each modified group in the sense strand is identical.
  • each flanking group has an equal number of nucleotides.
  • each flanking group is identical.
  • the nucleotides of said modified groups in the sense strand comprise a modified base.
  • the nucleotides of said modified groups comprise a modified phosphate backbone.
  • the nucleotides of said modified groups comprise a modified 2' position.
  • the antisense strand and the sense strand each comprise a plurality of modified groups, wherein each modified group consists of one or more identically modified nucleotides, wherein each modified group is flanked on one or both sides by a flanking group, wherein each said flanking group consists of one or more nucleotides that are either unmodified or modified in a manner different from the nucleotides of said modified group.
  • each modified group in the antisense strand and the sense strand are identical.
  • each flanking group in the antisense strand and the sense strand each have an equal number of nucleotides.
  • each flanking group in the antisense strand and in the sense strand are identical.
  • nucleotides of said modified groups in the antisense strand and the sense strand each comprise the same modified groups and the same flanking groups. In another embodiment, the nucleotides of said modified groups in the antisense strand and the sense strand each comprise a modified base. In another embodiment, the nucleotides of said modified groups in the antisense strand and the sense strand each comprise a modified phosphate backbone. In another embodiment, the nucleotides of said modified groups in the antisense strand and the sense strand each comprise a modified 2' position.
  • the modified groups and the flanking groups form a regular pattern on the antisense stand. In another aspect, the modified groups and the flanking groups form a regular pattern on the sense strand. In one embodiment, the modified groups and the flanking groups form a regular pattern on the both the antisense strand and the sense strand. In another embodiment, the modified groups and the flanking groups form a regular pattern on the antisense duplex region. In another aspect, the modified groups and the flanking groups form a regular pattern on the sense duplex region. In one embodiment, the modified groups and the flanking groups form a regular pattern on the both the antisense duplex region and the sense duplex region.
  • the pattern is a spatial or positional pattern.
  • a spatial or positional pattern means that (a) nucleotide(s) are modified depending on their position within the nucleotide sequence of a double-stranded portion. Accordingly, it does not matter whether the nucleotide to be modified is a pyrimidine or a purine.
  • a modified nucleotide is dependent upon: (a) its numbered position on a strand of nucleic acid, wherein the nucleotides are numbered from the 5 '-end to the 3 '-end with the 5 '-end nucleotide of the strand being position one (both the antisense strand and sense strand are numbered from their respective 5 '-end nucleotide), or (b) the position of the modified group relative to a flanking group.
  • the modification pattern will always be the same, regardless of the sequence which is to be modified.
  • the number of modified groups on the antisense strand is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.
  • the number of modified groups on the sense strand is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.
  • the number of flanking groups on the antisense strand of nucleic acid is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.
  • the number of flanking groups on the sense strand of nucleic acid is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.
  • the number of modified groups and the number of flanking groups on either or both the antisense strand and the sense strand are the same.
  • the number of modified groups on the antisense duplex region is selected 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13 or 14. In another embodiment, the number of modified groups on the sense duplex region is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13 or 14. In another embodiment, the number of flanking groups on the antisense duplex region of nucleic acid is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14. In another embodiment, the number of flanking groups on the sense duplex region of nucleic acid is selected from 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13 or 14. In one embodiment, the number of modified groups and the number of flanking groups on either or both the antisense duplex region and the sense duplex region are the same.
  • the number of modified groups and the number of flanking groups on a strand or on a duplex region are the same. In another embodiment, the number of modified groups and the number of flanking groups on a strand or on a duplex region are the same, wherein the number is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.
  • the number of nucleotides in a modified group is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14. In another embodiment, the number of nucleotides in a flanking group is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.
  • each modified group on both the antisense strand and the sense strand is identical. In one embodiment, each modified group on both the antisense duplex region and the sense duplex region is identical. In another embodiment, each modified group and each flanking group on both the antisense strand and the sense strand are identical. In one embodiment, each modified group and each flanking group on both the antisense duplex region and the sense duplex region are identical.
  • each modified group, each modified group position, each flanking group and each flanking group position on both the antisense strand and the sense strand are identical. In one embodiment, each modified group, each modified group position, each flanking group and each flanking group position on both the antisense duplex region and the sense duplex region are identical. In another embodiment, the modified groups on the antisense strand are complementary with the modified groups on the sense strand (the modified groups on the antisense strand and the sense strand are perfectly aligned across from one another). In another embodiment, there are no mismatches in the modified groups such that each modified group on the antisense strand is base paired with each modified group on the sense strand.
  • each modified group on the sense strand is shifted by 1, 2, 3, 4 or 5 nucleotides relative to the modified groups on the antisense strand. For example, if each modified group on the sense strand is shifted by one nucleotide and a modified group started at position one on the antisense strand, a modified group on the sense strand would begin at position two.
  • the modified groups of the antisense strand do not overlap the modified groups of the sense strand, i.e., no nucleotide of a modified group on the antisense strand is base paired with a nucleotide of a modified group on the sense strand.
  • deoxyribonucleotides at an end of a strand of nucleic acid are not considered when determining a position of a modified group, i.e., the positional numbering begins with the first ribonucleotide or modified ribonucleotide.
  • abasic nucleotides at an end of a strand of nucleic acid are not considered when determining a position of a modified group.
  • a modified group comprises a 5 '-end nucleotide of either or both of the antisense strand and the sense strand.
  • a flanking group comprises the 5 '-end nucleotide of either or both of the antisense strand and the sense strand.
  • the 5 '-end nucleotide of either or both of the antisense strand and the sense strand is unmodified.
  • a modified group comprises the 5 '-most nucleotide of either or both of the antisense duplex region and sense duplex region.
  • a flanking group comprises the 5 '-most nucleotide of either or both of the antisense duplex region or the sense duplex region.
  • the 5 '-most nucleotide of either or both of the antisense duplex region or the sense duplex region is unmodified.
  • the nucleotide at position 10 of the antisense strand is unmodified.
  • the nucleotide at position 10 of the sense strand is modified.
  • a modified group comprises the nucleotide at position 10 of the sense strand.
  • the modification at the 2' position is selected from the group comprising amino, fluoro, methoxy, alkoxy and Ci-C3-alkyl. In another embodiment, the modification is 2'-0-methyl.
  • each modified group consists of one nucleotide and each flanking group consists of one nucleotide.
  • each modified group on the antisense strand is aligned with a flanking group on the sense strand.
  • each modified group consists of one 2'-0-methyl modified nucleotide and each flanking group consists of one nucleotide. In one embodiment, each flanking group consists of one unmodified nucleotide. In one embodiment, each flanking group consists of one 2'-0-methyl modified nucleotide.
  • each modified group on both the antisense strand and the sense strand consists of one 2'-0-methyl modified nucleotide and each flanking group on both the antisense strand and the sense strand consists of one nucleotide, wherein no modified group on one strand is either aligned or both aligned and base paired with another modified group on the other strand and no flanking group on one strand is either aligned or both aligned and base paired with a flanking group on the other strand.
  • each modified group on each strand is either aligned or both aligned and based paired with a flanking group on the other strand.
  • the flanking group is unmodified.
  • the nucleotide of position one on the antisense strand is 2'-0-methyl modified.
  • the 5 '-most nucleotide of the antisense duplex region is 2'-0-methyl modified.
  • Modifications to phosphate backbone Another secondary aspect relates to modifications to a phosphate backbone.
  • All or a portion of the nucleotides of the siRNA of the invention may be linked through phosphodiester bonds, as found in unmodified nucleic acid.
  • a siRNA of the present invention may comprise a modified phosphodiester linkage.
  • the phosphodiester linkages of either the antisense stand or the sense strand may be modified to independently include at least one heteroatom selected from the group consisting of nitrogen and sulfur.
  • a phosphoester group connecting a ribonucleotide to an adjacent ribonucleotide is replaced by a modified group.
  • the modified group replacing the phosphoester group is selected from the group consisting of phosphothioate, methylphosphonate or phosphoramidate group.
  • all of the nucleotides of the antisense strand are linked through phosphodiester bonds. In another embodiment, all of the nucleotides of the antisense duplex region are linked through phosphodiester bonds. In another embodiment, all of the nucleotides of the sense strand are linked through phosphodiester bonds. In another embodiment, all of the nucleotides of the sense duplex region are linked through phosphodiester bonds. In another embodiment, the antisense strand comprises a number of modified phosphoester groups selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In another embodiment, the antisense duplex region comprises a number of modified phosphoester groups selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the sense strand comprises a number of modified phosphoester groups selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the sense duplex region comprises a number of modified phosphoester groups selected from 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the siRNA of the present invention may include nucleic acid molecules comprising one or more modified nucleotides, abasic nucleotides, acyclic or deoxyribonucleotide at the terminal 5 '- or 3 '-end on either or both of the sense or antisense strands.
  • the 5'- and 3 '-end nucleotides of both the sense and antisense strands are unmodified.
  • the 5 '-end nucleotide of the antisense strand is modified.
  • the 5 '-end nucleotide of the sense strand is modified.
  • the 3 '-end nucleotide of the antisense strand is modified. In another embodiment, the 3 '-end nucleotide of the sense strand is modified. In another embodiment, the 5 '-end nucleotide of the antisense strand and the 5 '-end nucleotide of the sense strand are modified. In another embodiment, the 3 '-end nucleotide of the antisense strand and the 3 '-end nucleotide of the sense strand are modified. In another embodiment, the 5 '-end nucleotide of the antisense strand and the 3 '-end nucleotide of the sense strand are modified.
  • the 3 '-end nucleotide of the antisense strand and the 5 '-end nucleotide of the sense strand are modified.
  • the 3 '-end nucleotide of the antisense strand and both the 5 '- and 3 '-end nucleotides of the sense strand are modified.
  • both the 5 '- and 3 '-end nucleotides of the antisense strand are modified.
  • both the 5 '- and 3 '-end nucleotides of the sense strand are modified.
  • the 5 '-end nucleotide of the antisense strand is phosphorylated. In another embodiment, the 5 '-end nucleotide of the sense strand is phosphorylated. In another embodiment, the 5 '-end nucleotides of both the antisense strand and the sense strand are phosphorylated. In another embodiment, the 5 '-end nucleotide of the antisense strand is phosphorylated and the 5 '-end nucleotide of the sense strand has a free hydroxyl group (5 ' -OH). In another embodiment, the 5 '-end nucleotide of the antisense strand is phosphorylated and the 5 '-end nucleotide of the sense strand is modified.
  • Modifications to the 5 '- and 3 '-end nucleotides are not limited to the 5 ' and 3 ' positions on these terminal nucleotides.
  • modifications to end nucleotides include, but are not limited to, biotin, inverted (deoxy) abasics, amino, fluoro, chloro, bromo, CN, CF, methoxy, imidazole, caboxylate, thioate, Ci to C 10 lower alkyl, substituted lower alkyl, alkaryl or aralkyl, OCF 3 , OCN, 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; SOCH 3 ; S0 2 CH 3 ; ON0 2 ; N0 2 , N 3 ; heterozycloalkyl; heterozycloalkaryl; amino alky lamino; polyalkylamino or substituted silyl, as, among others, described, e.g., in PCT patent application
  • alkyl means Ci-Ci 2 -alkyl and "lower alkyl” means Ci-C 6 -alkyl, including Ci-, C 2 -, C 3 -, C 4 -, C 5 - and C 6 -alkyl.
  • the 5 '-end of the antisense strand, the 5 '- end of the sense strand, the 3 '-end of the antisense strand or the 3 '-end of the sense strand is covalently connected to a prodrug moiety.
  • the moiety is cleaved in an endosome. In another the moiety is cleaved in the cytoplasm.
  • the terminal 3' nucleotide or two terminal 3 '-nucleotides on either or both of the antisense strand or sense strand is a 2'-deoxynucleotide.
  • the 2'-deoxynucleotide is a 2'-deoxy-pyrimidine.
  • the 2'- deoxynucleotide is a 2' deoxy-thymidine.
  • shRNA and linked siRNA Another aspect relates to shR A and linked siR A. It is within the present invention that the double-stranded structure is formed by two separate strands, i.e. the antisense strand and the sense strand. However, it is also with in the present invention that the antisense strand and the sense strand are covalently linked to each other. Such linkage may occur between any of the nucleotides forming the antisense strand and sense strand, respectively. Such linkage can be formed by covalent or non-covalent linkages. Covalent linkage may be formed by linking both strands one or several times and at one or several positions, respectively, by a compound preferably selected from the group comprising methylene blue and bifunctional groups.
  • Such bifunctional groups are preferably selected from the group comprising bis(2-chloroethyl)amine, N-acetly-N'-(p- glyoxylbenzoyl)cystamine, 4-thiouracile and psoralene.
  • the antisense strand and the sense strand are linked by a loop structure.
  • of the loop structure is comprised of a non-nucleic acid polymer.
  • the non-nucleic acid polymer is polyethylene glycol.
  • the 5 ' -end of the antisense strand is linked to the 3 ' -terminus of the sense strand.
  • the 3 ' -end of the antisense strand is linked to the 5 ' -end of the sense strand.
  • the loop consists of a nucleic acid.
  • locked nucleic acid LNA
  • PNA peptide nucleic acid
  • the nucleic acid is ribonucleic acid.
  • the 5 '-terminus of the antisense strand is linked to the 3 '-terminus of the sense strand.
  • the 3 '-end of the antisense strand is linked to the 5 '-terminus of the sense strand.
  • the loop consists of a minimum length of four nucleotides or nucleotide analogues. In one embodiment, the loop consists of a length of nucleotides or nucleotide analogues selected from 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14 or 15. In one embodiment, the length of the loop is sufficient for linking the two strands covalently in a manner that a back folding can occur through a loop structure or similar structure.
  • the ribonucleic acid constructs may be incorporated into suitable vector systems.
  • the vector comprises a promoter for the expression of RNAi.
  • the respective promoter is pol III and more preferably the promoters are the U6, HI, 7SK promoter as described in Good et al. (1997) Gene Ther, 4, 45-54.
  • the nucleic acid according to the present invention comprises a phosphorothioate internucleotide linkage.
  • a phosphorothioate internucleotide linkage is within 5 nucleotides from the 3 '-end or the 5 '-end of either or both of the antisense strand and the sense strand.
  • the antisense strand can comprise about one to about five phosphorothioate internucleotide linkages.
  • an overhang at the 3 '-end of the sense strand is selected from consisting of 1, 2, 3, 4 and 5 nucleotides in length. In one embodiment, an overhang at the 5'- end of the antisense strand is selected from consisting of 1, 2, 3, 4 and 5 nucleotides in length. In one embodiment, an overhang at the 5 '-end of the sense strand is selected from consisting of 1, 2, 3, 4 and 5 nucleotides in length.
  • the siRNA molecule is blunt-ended on both ends and has a length selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29 consecutive nucleotides.
  • the siRNA molecule is blunt-ended on one end and the double stranded portion of the siRNA molecule has a length selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29 consecutive nucleotides.
  • the siRNA molecule has overhangs on both ends and the double stranded portion of the siRNA molecule has a length selected from the group consisting of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29 consecutive nucleotides.
  • the siRNA molecule comprises an overhang, said overhang comprising at least one deoxyribonucleotide. In one embodiment, the siRNA molecule comprises an overhang, said overhang comprising two deoxyribonucleotides.
  • the siRNA molecule has overhangs on the 3 '-end of the antisense strand and at the 3 '-end of the sense strand, said overhangs comprising at least one deoxyribonucleotide. In one embodiment, the siRNA molecule has overhangs on the 3 '-end of the antisense strand and at the 3 '-end of the sense strand, said overhangs consisting two deoxyribonucleotides.
  • nucleotide(s) forming the overhang may be (a) desoxyribonucleotide(s), (a) ribonucleotide(s) or a combination thereof.
  • the antisense strand and/or the sense strand comprise a TT dinucleotide at the 3 ' end.
  • the nucleic acid of the present invention can be produced using routine methods in the art including chemically synthesis or expressing the nucleic acid either in vitro (e.g., run off transcription) or in vivo.
  • the siRNA is produced using solid phase chemical synthesis.
  • the nucleic acid is produced using an expression vector.
  • the expression vector produced the nucleic acid of the invention in the target cell. Accordingly, such vector can be used for the manufacture of a medicament. Methods for the synthesis of the nucleic acid molecule described herein are known to the ones skilled in the art.
  • PDN3 Protein kinase 3
  • the delivery vehicle may, in a further embodiment, encompass and thus deliver an siRNA which is targeting PKN3.
  • PKN3-specific siRNAs are, for example, described in international patent application WO 2008/009477.
  • Preferred embodiments are the following siRNAs, whereby the modification is only optional and any of the modifications described herein may be equally applied to and thus be realized by such PKN3-specific siRNAs.
  • the nucleotide indicated with a capital letter is a nucleotide which is 2'-0-methyl modified.
  • PKN3 (2) cUuGaGgAcUuCcUgGaCa (SEQ ID NO: 23)
  • PKN3 (3) uUgAgGaCuUcCuGgAcAa (SEQ ID NO: 26)
  • PKN3 (4) aGgAcUuCcUgGaCaAuGc (SEQ ID NO: 28)
  • PK 3 (6) gGgAcAcUuUgGgAaGgUc (SEQ ID NO: 32)
  • PKN3 (8): cUcCaGcCaUgCcUgCuUu (SEQ ID NO: 34)
  • PKN3-23-vl UuGuCcAgGaAgUcCuCaAgUcU (SEQ ID NO: 36)
  • PKN3-23-v2 GgCaUuGuCcAgGaAgUcCuCaA (SEQ ID NO: 38)
  • PKN3-23-v3 AuUgUcCaGgAaGuCcUcAaGuC (SEQ ID NO: 40)
  • PKN3-23-v4 CaUuGuCcAgGaAgUcCuCaAgU (SEQ ID NO: 42)
  • PKN3-23-v5 GcAuUgUcCaGgAaGuCcUcAaG (SEQ ID NO: 44)
  • siRNA can be delivered to cells, both in vitro and in vivo, by a variety of methods known to those of skill in the art, including direct contact with cells ("naked” siRNA) or by in combination with one or more agents that facilitate targeting or delivery into cells.
  • agents and methods include lipoplexes, liposomes, iontophoresis, hydrogels, cyclodextrins, nanocapsules, micro- and nanospheres and proteinaceous vectors (e.g., Bioconjugate Chem. (1999) 10: 1068-1074 and WO 00/53722).
  • the nucleic acid/vehicle combination may be locally delivered in vivo by direct injection or by use of an infusion pump.
  • the siRNA of the invention can be delivered in vivo by various means including intravenous subcutaneous, intramuscular or intradermal injection or inhalation.
  • the molecules of the instant invention can be used as pharmaceutical agents.
  • pharmaceutical agents prevent, modulate the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a subject.
  • compositions comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes).
  • PEG-modified, or long-circulating liposomes or stealth liposomes offer a method for increasing stability of a liposome or lipoplex solutions by preventing their aggregation and fusion.
  • the formulations also have the added benefit in vivo of resisting opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug.
  • MPS or RES mononuclear phagocytic system
  • liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al, Science 1995, 267, 1275-1276; Oku et al, 1995, Biochim. Biophys. Acta, 1238, 86-90).
  • the long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al, J. Biol. Chem. 1995, 42,24864-24780; Choi et al, International PCT Publication No.
  • WO 96/10391 Ansell et al, International PCT Publication No. WO 96/10390; Holland et al, International PCT Publication No. WO 96/10392).
  • Long-circulating liposomes also protect the siRNA from nuclease degradation.
  • the siRNA of the present invention may be formulated as pharmaceutical compositions.
  • the pharmaceutical compositions may be used as medicaments or as diagnostic agents, alone or in combination with other agents.
  • one or more siRNAs of the invention can be combined with a delivery vehicle (e.g., liposomes) and excipients, such as carriers, diluents. Other agents such as preservatives and stabilizers can also be added.
  • a delivery vehicle e.g., liposomes
  • excipients such as carriers, diluents.
  • Other agents such as preservatives and stabilizers can also be added.
  • Methods for the delivery of nucleic acid molecules are known in the art and described, e.g., in Akhtar et al, 1992, Trends Cell Bio., 2, 139; Delivery Strategies for Antisense Oligonucleotide Therapeutics, ed. Akhtar, 1995, Maurer et al, 1999, Mol. Memb.
  • siRNA of the present invention can also be administered in combination with other therapeutic compounds, either administrated separately or simultaneously, e.g., as a combined unit dose.
  • the invention includes a pharmaceutical composition comprising one or more siRNA according to the present invention in a physio logically/pharmaceutically acceptable excipient, such as a stabilizer, preservative, diluent, buffer, and the like.
  • a physio logically/pharmaceutically acceptable excipient such as a stabilizer, preservative, diluent, buffer, and the like.
  • a unit dose contains between about 0.01 mg/kg and about 100 mg/kg body weight of siRNA.
  • the dose of siRNA is about 10 mg/kg and about 25 mg/kg body weight.
  • the dose of siRNA is about 1 mg/kg and about 10 mg/kg body weight.
  • the dose of siRNA is about 0.05 mg/kg and about 5 mg/kg body weight.
  • the dose of siRNA is about 0.1 mg/kg and about 5 mg/kg body weight.
  • the dose of siRNA is about 0.1 mg/kg and about 1 mg/kg body weight.
  • the dose of siRNA is about 0.1 mg/kg and about 0.5 mg/kg body weight.
  • the dose of siRNA is about 0.5 mg/kg and about 1 mg/kg body weight.
  • the pharmaceutical composition is a sterile injectable aqueous suspension or solution. In one aspect, the pharmaceutical composition is in lyophilized form. In one embodiment, the pharmaceutical composition comprises lyophilized lipoplexes, wherein the lipoplexes comprises a siRNA of the present invention. In another embodiment, the pharmaceutical composition comprises an aqueous suspension of lipoplexes, wherein the lipoplexes comprises a siRNA of the present invention.
  • compositions and medicaments of the present invention may be administered to a subject (mammal) in the disclosed methods of treatment.
  • the mammal is selected from the group consisting humans, dogs, cats, horses, cattle, pig, goat, sheep, mouse, rat, hamster and guinea pig.
  • the mammal is a human.
  • the mammal is a non-human mammal.
  • the present invention is related to lipoplexes comprising a siRNA according to the present invention.
  • lipoplexes consist of siRNA and liposomes.
  • Such lipoplexes may be used to deliver the siRNA of the invention to a target cell either in vitro or in vivo.
  • the lipoplex has a zeta-potential of about 40 to 55 mV, preferably about 45 to 50 mV.
  • the size of the lipoplex according to the present invention is about 80 to 200 nm, about 100 to 140 nm or about 110 nm to 130 nm, as determined by dynamic light scattering (QELS) such as, e. g., by using an N5 submicron particle size analyzer from Beckman Coulter according to the manufacturer's recommendation.
  • QELS dynamic light scattering
  • the liposome as forming part of the lipoplex is a positively charged liposome consisting of:
  • the lipoplex and lipid composition forming the liposomes is preferably in a carrier however, the lipoplex can also be present in a lyophilised form.
  • the lipid composition contained in a carrier usually forms a dispersion. More preferably, the carrier is an aqueous medium or aqueous solution as also further characterised herein.
  • the lipid composition typically forms a liposome in the carrier, whereby such liposome preferably also contains the carrier inside.
  • the lipid composition contained in the carrier and the carrier, respectively, preferably has an osmolality of about 50 to 600 mosmole/kg, preferably about 250 - 350 mosmole/kg, and more preferably about 280 to 320 mosmole/kg.
  • the liposomes preferably are formed by the first lipid component and optionally also by the second lipid component, preferably in combination with the first lipid component, preferably exhibit a particle size of about 20 to 200 nm, preferably about 30 to 100 nm, and more preferably about 40 to 80 nm. It is noted that the size of the particles follows a certain statistical distribution.
  • a further optional feature of the lipid composition in accordance with the present invention is that the pH of the carrier is preferably from about 4.0 to 6.0. However, also other pH ranges such as from 4.5 to 8.0, preferably from about 5.5 to 7.5 and more preferably about 6.0 to 7.0 are within the present invention.
  • the lipid composition of the present invention may comprise one or several of the following sugars: sucrose, trehalose, glucose, galactose, mannose, maltose, lactulose, inulin and raffmose, whereby sucrose, trehalose, inulin and raffinose are particularly preferred.
  • the osmolality mostly adjusted by the addition of sugar is about 300 mosmole/kg which corresponds to a sucrose solution of 270 mM or a glucose solution of 280 mM.
  • the carrier is isotonic to the body fluid into which such lipid composition is to be administered.
  • the term that the osmolality is mostly adjusted by the addition of sugar means that at least about 80 %, preferably at least about 90 % of the osmolality is provided by said sugar or a combination of said sugars.
  • the pH of the lipid composition of the present invention is adjusted, this is done by using buffer substances which, as such, are basically known to the one skilled in the art.
  • buffer substances which, as such, are basically known to the one skilled in the art.
  • basic substances are used which are suitable to compensate for the basic characteristics of the cationic lipids and more specifically of the ammonium group of the cationic head group.
  • the particle size of such lipid composition and the liposomes formed by such lipid composition is preferably determined by dynamic light scattering such as by using an N5 submicron particle size analyzer from Beckman Coulter according to the manufacturer's recommendation.
  • the lipid composition contains one or several nucleic acid(s), such lipid composition usually forms a lipoplex (liposome-nucleic acid complex).
  • the more preferred concentration of the overall lipid content in the lipoplex in preferably isotonic 270 mM sucrose or 280 mM glucose is from about 0.01 to 100 mg/ml, preferably 0.01 to 40 mg/ml and more preferably 0.01 to 25 mg/ml. It is to be acknowledged that this concentration can be increased so as to prepare a reasonable stock, typically by a factor of 2 to 3. It is also within the present invention that based on this, a dilution is prepared, whereby such dilution is typically made such that the osmolality is within the range specified above.
  • the dilution is prepared in a carrier which is identical or in terms of function and more specifically osmolality similar to the carrier used in connection with the lipid composition or in which the lipid composition is contained.
  • the lipid composition of the present invention whereby the lipid composition also comprises a nucleic acid, preferably a functional nucleic acid such as, but not limited to, a siRNA
  • the concentration of the functional nucleic acid, preferably of siRNA in the lipid composition is about 0.2 to 0.4 mg/ml, preferably 0.28 mg/ml
  • the total lipid concentration is about 1.5 to 2.7 mg/ml, preferably 2.17 mg/ml.
  • this mass ratio between the nucleic acid fraction and the lipid fraction is particularly preferred, also with regard to the charge ratio thus realized.
  • the mass ratio and the charge ratio, respectively, realized in this particular embodiment is preferably maintained despite such concentration or dilution.
  • Such concentration as used in, for example, a pharmaceutical composition can be either obtained by dispersing the lipid in a suitable amount of medium, preferably a physiologically acceptable buffer or any carrier described herein, or can be concentrated by appropriate means.
  • appropriate means are, for example, ultra filtration methods including cross-flow ultra- filtration.
  • the filter membrane may exhibit a pore width of 1,000 to 300,000 Da molecular weight cut-off (MWCO) or 5 nm to 1 ⁇ . Preferred is a pore width of about 10,000 to 100,000 Da MWCO. It will also be acknowledged by the one skilled in the art that the lipid composition more specifically the lipoplexes in accordance with the present invention may be present in a lyophilized form.
  • Such lyophilized form is typically suitable to increase the shelve life of a lipoplex.
  • the sugar added, among others, to provide for the appropriate osmolality is used in connection therewith as a cryo -protectant.
  • the aforementioned characteristics of osmolality, pH as well as lipoplex concentration refers to the dissolved, suspended or dispersed form of the lipid composition in a carrier, whereby such carrier is in principle any carrier described herein and typically an aqueous carrier such as water or a physiologically acceptable buffer, preferably an isotonic buffer or isotonic solution.
  • the delivery system described therein is a composition comprising a lipid composition, wherein the lipid composition consists of
  • n is any one of 1, 2, 3, and 4, wherein m is any one of 1 , 2 and 3,
  • Y " is an anion, wherein each of Rl and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II)
  • each of R3 and R4 is individually and independently linear C13-C17 alkyl
  • p is any integer from 15 to 130; a PEGylated ceramide of formula (III)
  • R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV)
  • each of R6 and R7 is individually and independently linear CI 1-C17 alkyl, and r is any integer from 15 to 130.
  • Another preferred embodiment of the delivery vehicle is one comprising the following lipid composition: 70 mole % of -arginyl-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide trihydrochloride
  • One aspect of the present invention provides a means for the treatment of pre-eclampsia or aged macular degeneration.
  • the delivery vehicle as disclosed herein and more preferably the lipid composition defined herein as AtuPLEX.
  • the treatment of pre-eclampsia is, without wishing to be bound by any theory based on the observation that any payload of said delivery vehicle is contained within the maternal body of a pregnant female mammal and is not passed-on to the embryo of the pregnant female mammal.
  • a preferred payload is a nucleic acid such as an siRNA and an siRNA directed to sFltl and/or PK 3 as described herein.
  • such means is also a nucleic acid such as to siRNA directed to sFltl and/or PKN3.
  • such means is a lipoplex comprising a delivery vehicle as disclosed herein and an siRNA as disclosed herein, wherein preferably such siRNA is a sFltl -specific siRNA or a PKN3 -specific siRNA as described herein.
  • the siRNA molecules can be used in combination with other therapeutic agents to enhance the therapeutic effects of a given treatment modality.
  • the present invention provides reagents and methods useful for treating diseases and conditions characterized by undesirable or aberrant levels of sFltl activity in a cell.
  • the means described herein and delivery vehicle as disclosed herein in particular is also suitable for the diagnosis of a disease related to the malfunctions of sFlt-1 gene such as aged macular degeneration and preferably pre-eclampsia.
  • a disease related to the malfunctions of sFlt-1 gene such as aged macular degeneration and preferably pre-eclampsia.
  • the payload of the delivery vehicle is effective as a diagnostic agent, it will be possible to diagnose, more specifically by means of radioimmuno techniques, fluorescence techniques and/or imaging techniques diseases and disorders of the maternal body, or by way of exclusion, of the fetal body.
  • the payload of the delivery vehicle will encompass a detectable marker such as, for example, a radio label or a fluorescence label.
  • the payload of the delivery vehicle for the purpose of diagnosis can be, for example, a small molecule, a peptide, a polypeptide, a protein, an oligonucleotide, a polynucleotide or a nucleic acid.
  • Human endothelial cells were cultivated according to standard protocol.
  • AtuPLEX is a lipid composition containing
  • DACC10 is a lipid composition containing
  • Cationic liposomes comprising the novel cationic lipid AtuFECTOl which is -Z-arginyl-2,3- Z-diaminopropionic acid-N-palmityl-N-oleyl-amide trihydrochloride, Atugen AG (Berlin), the neutral/helper lipid phospholipid l,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhyPE) (Avanti Polar Lipids Inc., Alabaster, AL) and the PEGylated lipid N-(Carbonyl- methoxypolyethylenegly co 1-2000)- 1 ,2-distearoyl-sn-glycero-3-phospho-ethanolamine sodium salt (DSPE-PEG) (Lipoid GmbH, Ludwigshafen, Germany) in a molar ratio of 50/49/1 were prepared by lipid film re-hydration in 300mM sterile R ase-free sucrose solution to a
  • the multilamellar dispersion was further processed by high pressure homogenization (22 cycles at 750 bar and 5 cycles at 1000 bar) using an EmulsiFlex C3 device (Avestin, Inc., Ottawa, Canada).
  • EmulsiFlex C3 device Avestin, Inc., Ottawa, Canada.
  • siRNA-lipoplexes AtuPLEX
  • the obtained liposomal dispersion was mixed with an equal volume of a 0.5625 mg/ml solution of siRNA in 300 mM sucrose, resulting in a calculated charge ratio of nucleic acid backbone phosphates to cationic lipid nitrogen atoms of approximately 1 to 4.
  • the size of the liposome and the lipoplex-dispersion was determined by Quasi Elastic Light Scattering (N5 Submicron Particle Size Analyzer, Beckman Coulter, Inc., Miami, FL) and the zeta potential was measured using a Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK).
  • CD31-23-mr-4B cAgUaUcAgAaUuUcAgCaAgAu- (SEQ ID NO: 47)
  • Tissues were paraffin embedded, sectioned and counter-stained with nuclear stain Sytox green (Molecualr Probes, 100 nM) using standard protocols. Stained tissues were directly examined by epifluorescence with a Zeiss LSM510 Meta confocal microscope.
  • siRNA lipolexes consisting of AtuPLEX or DACCIO as lipid composition and thus delivery vehicle, as described previously (Santel, A et al. (2006). Gene Ther 13: 1222-1234)). Briefly, about 12 hours after cell seeding different amounts of lipoplex formulations diluted in 10% serum-containing medium were added to the cells to achieve transfection concentrations in a final concentration of 20 nM siRNA. 24 days after transfection cells were lysed and total RNA was isolated for qRT-PCR to determine target gene expression.
  • mice stage 13.5 were treated with single dose of a lipoplex consisting of AtuPLEX and PKN3-specific siRNA (2.8 mg siRNA/kg body weight )).
  • siRNA content in liver, placenta, lung and embryo was determined by quantitative capture probe ELISA one hour after treatment (Aleku et al. 2008).
  • siRNA molecules which are directed to the mRNA encoding sFLTl and the siRNA molecules directed to Luciferase which were used in connection with the experiments and examples described herein, were synthesized by BioSpring (Frankfurt a. M., Germany) and are indicated in Fig. 1 in terms of the sequences of both the first strand (being the antisense strand) and the second strand (being the sense strand) forming the double-stranded nucleic acid molecules of the present invention.
  • Luciferase-specific siRNA was formed by the following two strands:
  • PKN3 siRNA molecule was used in combination with AtuPLEX or DACCIO fin in in vivo studies:
  • A stands for the antisense strand which is also referred to herein as the first strand
  • B stands for the sense strand which is also referred to herein as the second strand.
  • the antisense strands can be modified at the 2' position (e.g., with a 2'-0-methyl group) on one or more odd numbered nucleotide (or on each odd numbered nucleotide) and one or more even numbered nucleotides remain unmodified (e.g., a OH group is present at the 2' position on each of the unmodified nucleotides, for example each of the unmodified nucleotides is unmodified).
  • Sense strands can be modified on one or more even numbered nucleotide (or on each even numbered nucleotide) at the 2' position (e.g., with a 2'-0-methyl group) and one or more odd numbered nucleotides can remain unmodified (e.g., a OH group is present at the 2' position on each of the unmodified nucleotides, for example each of the odd numbered nucleotides is unmodified).
  • Alternative embodiments provide for antisense strands (as set forth above) that are modified at the 2' position (e.g., with a 2'-0-methyl group) on one or more even numbered nucleotide (or on each even numbered nucleotide) and sense strands are modified on one or more odd numbered nucleotide (or on each odd numbered nucleotide) at the 2' position (e.g., with a 2'-0-methyl group).
  • One or more unmodified nucleotide is present in both the sense and antisense strands in these alternative embodiments (e.g., the unmodified nucleotides have a OH group at the 2' position in each of these alternative embodiments).
  • each odd numbered nucleotide is unmodified in the antisense strand and each even numbered nucleotide is unmodified in the sense strand for the alternative embodiments discussed in this paragraph.
  • Fig. 1 The siRNA molecules of Fig. 1 were tested in vitro for inhibition of sFltl target expression in cell cultures using degradation of human sFltl mRNA as read-out. The results are indicated in Fig. 2 where the level of human sFltl mRNA is normalized relative to the level of human sFltl mRNA in untreated cells. As may be taken from Fig.
  • siRNA sFltl hm4 consisting of sFLTl-hm-4A and sFLTl-hm-4B was particularly effective, whereby siRNAs sFltl hm3 consisting of sFLTl-hm-3A and sFLTl-hm3B and sFltl hml consisting of sFLTl- hm-3A and sFLTl-hm-3B also exhibited some efficiency.
  • siRNA distribution was determined in pregnant mice (El 3.5) receiving a single dose of a lipoplex consisting of AtuPLEX and PKN3-specific siRNA. The result is shown for two mice in Fig. 3. As may be taken from Fig. 3 siRNA is found in maternal tissues like lungs and liver, but not in the embryo. Significant amounts of siRNAs were detected in all placentas of mice treated with AtuPLEX.
  • siRNA Cy3 staining is detectable in the labyrinth layer of the placenta.
  • the labyrinth layer is the region where maternal and fetal blood vessels are in closest proximity and gas and nutrient exchange takes place.
  • Fig. 5 it may be taken from Fig. 5 that in the placenta only maternal blood vessels are stained with Cy3 labeled siRNA, whereas fetal blood vessels are not stained; also umbilichord is also free of Cy3 labeled siRNA.
  • Example 5 Animal studies - knock-down of sFltl by lipoplexes consisting of sFLTl- targeting siRNA and either AtuPLEX or DACC10
  • sFltl and PKN3 in lungs of pregnant mice (stage 13,5) treated with siRNA targeting either sFltl ("sFLTl-hm4") or PKN3 ("PKN3") together with either AtuPLEX or DACC10 as delivery vehicle (forming a lipoplex with the respective siRNA), is shown in Fig. 7.
  • sFltl and PKN3 sFLT-1 target gene inhibition can be measured in lungs of pregnant mice.
  • DACC10 is more potent in reducing target gene expression in lungs than AtuPLEX.
  • sFltl and PKN3 in placentas of pregnant mice are shown in Fig. 8, whereby four placentas per mother were analysed).
  • sFltl expression in placentas is reduced in those groups where AtuPLEX was used as the delivery vehicle.
  • Preeclampsia was induced in rats by mating female rats transgenic for human angiotensinogen with male rats transgenic for human renin (Bohlender et al, 2000). Pregnant rats develop hypertension on day 13 of gestation (the day of plug is assigned dl of gestation), albuminuria and intrauterine growth restriction.
  • Pregnant rats develop hypertension on day 13 of gestation (the day of plug is assigned dl of gestation), albuminuria and intrauterine growth restriction.
  • heart rate and ambulatory activity radiotelemetric systems were implanted into the infra-renal aorta and harbored in the abdominal cavity. Rats were anaesthetized for telemetry implantation, tail cuff measurements, treatments with AtuPLEX and termination using isoflurane.
  • Transgenic pregnant rats received treatments with either isotonic sucrose (270 mM) as vehicle control or with AtuPLEX (1.4 mg/kg) on day 7, 10, 13, 16, and day 19 of gestation. From day 17 to day 18 of gestation animals were kept in metabolic cages for urine collection. Transgenic animals from this study were sacrificed on day 21 of gestation. Maternal and fetal organs of interest were collected; weight and selected tissues were snap frozen. Urinary rat albumin from day 17/18 was measured using an ELISA kit from CellTrend, Germany. All animal studies and study protocols were approved by local authorities (Landetician f. vom mechanically, Berlin).
  • sFLTl GGGAAGAGATCCTTCGGAAGA (forward) (SEQ ID NO. 60), GAGATCCGAGAGAAAATAGCCTTTT (reverse) (SEQ ID. NO. 61), AGAAGTTCTCGTTAGAGGTGAGCACTGCAGC (probe) (SEQ ID NO. 62).
  • 18S AC ATC C AAGG A AGGC AGC AG (forward) (SEQ ID NO. 63),
  • AtuPLEX ystemic administration of AtuPLEX in pregnant rats delivers siRNA to sthe mother, placental tissues, but not fetal tissues (see Figure 9,10,11 for biodistribution study with siRNA-Cy3 labeled AtuPLEX.
  • siRNA delivered by AtuPLEX is detected in the spongio-trophoblast layer (Fig.10). This is the part of the placenta were sFLT-1 expression is induced during pregnancy and particularly in preeclampsia. (sFltl is a bio marker and also a mediator of preeclampsia).
  • AtuPLEX/sFLtl siRNA formulation of the presetn invention reduces sFlt-1 expression in pregnant rats (Fig. 13).
  • AtuPLEX/sFLtl siRNA formulation reduces blood pressure (which is life treatening for mother and child in severe case of preeclampsia) see Fig. 14, but at the same time the well being of the mother or of the foetus are not adversely affected by AtuPLEX (Fig. 14D, 15, 16 and Fig. 17, 18 respectively .)
  • siRNA-lipoplexes for cancer therapy. Gene Ther. 13 : 1360-70.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques et leurs utilisations. L'invention concerne, en particulier, une composition lipidique servant à administrer un agent thérapeutique au placenta d'un mammifère femelle et destinée à être utilisée dans une méthode de traitement d'une maladie telle que la prééclampsie. L'invention concerne également des ARN interférents courts pour la prévention ou le traitement de telles maladies.
PCT/EP2015/078107 2014-11-28 2015-11-30 Moyens pour le traitement de la prééclampsie WO2016083623A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14004031.2 2014-11-28
EP14004031 2014-11-28

Publications (1)

Publication Number Publication Date
WO2016083623A1 true WO2016083623A1 (fr) 2016-06-02

Family

ID=52002649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/078107 WO2016083623A1 (fr) 2014-11-28 2015-11-30 Moyens pour le traitement de la prééclampsie

Country Status (1)

Country Link
WO (1) WO2016083623A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049349A1 (fr) * 2015-09-25 2017-03-30 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research Méthode de traitement et de prophylaxie
US20210052617A1 (en) * 2018-01-16 2021-02-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
EP4035659A1 (fr) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes destinés à l'administration d'agents thérapeutiques
US20240084297A1 (en) * 2016-08-12 2024-03-14 University Of Massachusetts Conjugated oligonucleotides
US12049627B2 (en) 2017-06-23 2024-07-30 University Of Massachusetts Two-tailed self-delivering siRNA
US12077755B2 (en) 2015-08-14 2024-09-03 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000320A2 (fr) * 2003-06-27 2005-01-06 Atugen Ag Induction d'une lyse cellulaire au moyen d'acide ribonucleique a double brin
WO2005105152A2 (fr) * 2004-05-05 2005-11-10 Atugen Ag Lipides, complexes lipidiques et utilisations correspondantes
WO2006069782A2 (fr) * 2004-12-27 2006-07-06 Silence Therapeutics Ag. Complexes lipidiques revetus et leur utilisation
WO2007121947A1 (fr) * 2006-04-20 2007-11-01 Silence Therapeutics Ag. Préparations de lipoplex pour administration spécifique sur l'endothélium vasculaire
WO2008009477A2 (fr) * 2006-07-21 2008-01-24 Silence Therapeutics Ag Moyen destiné à inhiber l'expression de la protéine kinase 3
WO2009051659A2 (fr) * 2007-10-12 2009-04-23 Intradigm Corporation Molécules sirna thérapeutiques destinées à réduire l'expression vegfr1 in vitro et in vivo
WO2010034487A2 (fr) * 2008-09-23 2010-04-01 Silence Therapeutics Ag Moyen d’inhibition de l’expression d’orc-1
WO2010094491A1 (fr) * 2009-02-18 2010-08-26 Silence Therapeutics Ag Moyen d'inhibition de l'expression de ang2
WO2013170960A1 (fr) * 2012-05-16 2013-11-21 Silence Therapeutics Ag Utilisation de vegfr1 en tant que biomarqueur pour l'administration d'un inhibiteur de pkn3

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000320A2 (fr) * 2003-06-27 2005-01-06 Atugen Ag Induction d'une lyse cellulaire au moyen d'acide ribonucleique a double brin
WO2005105152A2 (fr) * 2004-05-05 2005-11-10 Atugen Ag Lipides, complexes lipidiques et utilisations correspondantes
WO2006069782A2 (fr) * 2004-12-27 2006-07-06 Silence Therapeutics Ag. Complexes lipidiques revetus et leur utilisation
WO2007121947A1 (fr) * 2006-04-20 2007-11-01 Silence Therapeutics Ag. Préparations de lipoplex pour administration spécifique sur l'endothélium vasculaire
WO2008009477A2 (fr) * 2006-07-21 2008-01-24 Silence Therapeutics Ag Moyen destiné à inhiber l'expression de la protéine kinase 3
WO2009051659A2 (fr) * 2007-10-12 2009-04-23 Intradigm Corporation Molécules sirna thérapeutiques destinées à réduire l'expression vegfr1 in vitro et in vivo
WO2010034487A2 (fr) * 2008-09-23 2010-04-01 Silence Therapeutics Ag Moyen d’inhibition de l’expression d’orc-1
WO2010094491A1 (fr) * 2009-02-18 2010-08-26 Silence Therapeutics Ag Moyen d'inhibition de l'expression de ang2
WO2013170960A1 (fr) * 2012-05-16 2013-11-21 Silence Therapeutics Ag Utilisation de vegfr1 en tant que biomarqueur pour l'administration d'un inhibiteur de pkn3

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, 15 January 2011 (2011-01-15), XP055247131, Retrieved from the Internet <URL:http://www.genengnews.com/keywordsandtools/print/1/21567/> [retrieved on 20160203] *
HEYDARIAN M ET AL: "Novel Splice Variants of sFlt1 are Upregulated in Preeclampsia", PLACENTA, W.B. SAUNDERS, GB, vol. 30, no. 3, 1 March 2009 (2009-03-01), pages 250 - 255, XP025949020, ISSN: 0143-4004, [retrieved on 20090114], DOI: 10.1016/J.PLACENTA.2008.12.010 *
MASABUMI SHIBUYA: "Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia", PROCEEDINGS OF THE JAPAN ACADEMY. SERIES B, PHYSICAL ANDBIOLOGICAL SCIENCES, vol. 87, no. 4, 1 January 2011 (2011-01-01), JP, pages 167 - 178, XP055247140, ISSN: 0386-2208, DOI: 10.2183/pjab.87.167 *
ROSARIO F J ET AL: "Gene targeting in primary human trophoblasts", PLACENTA, vol. 33, no. 10, 2012, pages 754 - 762, XP028936968, ISSN: 0143-4004, DOI: 10.1016/J.PLACENTA.2012.07.003 *
SANTEL A ET AL: "RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 13, no. 18, 1 September 2006 (2006-09-01), pages 1360 - 1370, XP002443322, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3302778 *
SHAKIL AHMAD ET AL: "Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis", VASCULAR CELL, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 1, 13 July 2011 (2011-07-13), pages 15, XP021093119, ISSN: 2045-824X, DOI: 10.1186/2045-824X-3-15 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077755B2 (en) 2015-08-14 2024-09-03 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
WO2017049349A1 (fr) * 2015-09-25 2017-03-30 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research Méthode de traitement et de prophylaxie
US20240084297A1 (en) * 2016-08-12 2024-03-14 University Of Massachusetts Conjugated oligonucleotides
EP4035659A1 (fr) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes destinés à l'administration d'agents thérapeutiques
US12049627B2 (en) 2017-06-23 2024-07-30 University Of Massachusetts Two-tailed self-delivering siRNA
US20210052617A1 (en) * 2018-01-16 2021-02-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
US11844808B2 (en) * 2018-01-16 2023-12-19 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia

Similar Documents

Publication Publication Date Title
US9458461B2 (en) Means for inhibiting the expression of ANG2
WO2016083623A1 (fr) Moyens pour le traitement de la prééclampsie
CN104080794B (zh) RNAi试剂、组合物及其用于治疗甲状腺素运载蛋白(TTR)相关疾病的使用方法
CA2917320C (fr) Arnsi specifique du gene associe a une maladie respiratoire, structure oligo-arn double helice contenant l&#39;arnsi, composition contenant cette structure pour prevenir ou traiter un e maladie respiratoire
KR20180128423A (ko) 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR20220156880A (ko) Angptl3 발현을 저해하기 위한 조성물 및 방법
KR20220024153A (ko) 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료
US20230357774A1 (en) Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
AU2020358016A1 (en) Chemical modifications of small interfering RNA with minimal fluorine content
WO2017135397A1 (fr) Oligonucléotide antisens destiné à supprimer l&#39;expression du facteur du complément b
JP2019196384A (ja) ＮＯＴＣＨ １特異的なｓｉＲＮＡ分子
CN114728018A (zh) 亨廷顿(HTT)iRNA药剂组合物及其使用方法
KR102575703B1 (ko) Wfdc2의 발현을 조절하는 안티센스 화합물
TW202411427A (zh) 用於抑制細胞中agt表現之核酸
KR20200014320A (ko) Apcs의 발현을 억제하는 핵산
TW202305134A (zh) 杭丁頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
US11634715B2 (en) Methods and compositions for treating bile duct paucity-associated conditions
KR20210144601A (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물
US11952574B2 (en) Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression
WO2016083624A1 (fr) Moyens d&#39;inhibition de l&#39;expression d&#39;edn1
CN116478997B (zh) 用于抑制FGL1的siRNA及其修饰物与应用
RU2804776C2 (ru) СРЕДСТВА ДЛЯ РНКи, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ТРАНСТИРЕТИНОМ (TTR)
KR20230042646A (ko) Wfdc2의 발현을 조절하는 안티센스 화합물
KR20240138996A (ko) Wfdc2의 발현을 조절하는 안티센스 화합물을 포함하는 간질환 예방 또는 치료용 약학 조성물
CN116615541A (zh) 用于抑制plp1表达的组合物和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15804379

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15804379

Country of ref document: EP

Kind code of ref document: A1